Clark WL, et al. - In this study, investigators analyzed 202 subjects to evaluate the baseline symptoms associated with early visual acuity (VA) gains after ranibizumab treatment for retinal vein occlusion (RVO). They observed that the candidates achieved best-corrected VA (BCVA) of 20/40 or better in 59 days. They also noted that the median time for subjects to gain 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters was 63 days. Greater total macular volume and the presence of subretinal fluid at baseline were also found associated with more rapid vision gains.